Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 3/20 | 1.00 |
| ▸ | FBP1 | P09467 | 3/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9423 | 1.00 | EGFR (1.00) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL30363011 | 1.00 | EGFR (1.00) | EGFRKDRERBB2FBP1SRC | |
| Hydrochloric Acid SCHEMBL29369196 | 0.99 | EGFR (1.00) | EGFRKDRERBB2FBP1SRC | |
| Hydrochloric Acid SCHEMBL93918 | 0.99 | EGFR (1.00) | EGFRKDRERBB2FBP1SRC | |
| Hydrochloric Acid SCHEMBL30362813 | 0.99 | EGFR (1.00) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL12963484 | 0.93 | FBP1 (0.91) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL8349430 | 0.92 | EGFR (0.91) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL4232360 | 0.91 | FBP1 (0.84) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL22367416 | 0.91 | FBP1 (1.00) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL4229994 | 0.90 | EGFR (0.82) | EGFRKDRERBB2FBP1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | GENASE THERAPEUTICS B V (NL) | 2025-12-25 | — | — | US | disclosed |
| EP-4469461-B1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B V (NL) | 2025-10-15 | — | — | EP | disclosed |
| US-20250195668-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4469461-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | Genase Therapeutics B.V. (NL) | 2024-12-04 | — | — | EP | disclosed |
| CN-118946568-A | Tetrahydropyranopyrazole derivatives for the treatment of cancer and viral infections | 格纳赛治疗有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114656573-B | Deimmunized shiga toxin a subunit scaffolds and cell targeting molecules comprising the same | 分子模板公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-4320126-A2 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | The Broad Institute, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022225728-A9 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022225728-A2 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20220281926-A1 | DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2022-09-08 | — | — | US | disclosed |
| CN-114656573-A | Deimmunized shiga toxin a subunit scaffolds and cell targeting molecules comprising them | 分子模板公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11365223-B2 | De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same | MOLECULAR TEMPLATES, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20220185903-A1 | Novel bispecific binding molecule and drug conjugate thereof | NANTONG YICHEN BIOPHARMA. CO. LTD. (CN) | 2022-06-16 | — | — | US | disclosed |
| US-20220162271-A1 | HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS | MOLECULAR TEMPLATES, INC. | 2022-05-26 | — | — | US | disclosed |
| CN-107849096-B | Deimmunized shiga toxin a subunit scaffolds and cell targeting molecules comprising them | 分子模板公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3974424-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | Genase Therapeutics B.V. (NL) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022020588-A9 | CLINICAL METHODS FOR USE OF HER2 BINDING MOLECULES | MOLECULAR TEMPLATES, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195668-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | EGFR 3560/4885KDR 3633/4885ERBB2 1173/4885 |
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | CCNA1, KRAS, RSU1 | EGFR 1747/4885KDR 2474/4885ERBB2 2129/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | EGFR 2685/4885KDR 1640/4885ERBB2 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.